[PRNewswire] Novavax to Participate in Fireside Chat at Devex @ UNGA 76
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
(GAITHERSBURG, Md., Sept. 20, 2021 PRNewswire=연합뉴스) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access.
Interview details are as follows:
Date: Tuesday, September 21, 2021
Time: 8:50 - 9:05 a.m.
Location: Livestream [https://pages.devex.com/devex-at-unga-76.html ]
Title: Fireside chat: A status report on the COVID-19 vaccine rollout
Novavax panelist: John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Moderator: Jenny Lei Ravelo, Senior Reporter, Devex
For more information or to register for the fireside chat, visit:
https://pages.devex.com/devex-at-unga-76.html
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter [https://twitter.com/novavax ] and LinkedIn [https://www.linkedin.com/company/novavax ].
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
Novavax Logo
Source: Novavax, Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- [속보] "전국 18곳 사전투표소 등지서 불법카메라 의심 장치 발견" | 연합뉴스
- 한동훈 "조국 검찰개혁은 1건에 22억 땡기는 전관예우 양성화"(종합) | 연합뉴스
- 이재명 "귀한 선거 기간에 법원 출석…정치 검찰이 노린 결과" | 연합뉴스
- 尹 "GTX 개통, 국민교통 혁명…요금부담 낮춰 2천∼3천원대로"(종합2보) | 연합뉴스
- '돈봉투 의혹' 송영길 보석청구 기각…법원 "증거인멸 염려"(종합2보) | 연합뉴스
- 차기 의협회장, '조건없는 대화' 제안에 "논평할 가치도 없어"(종합) | 연합뉴스
- '도피논란' 이종섭, 대사 임명 25일만에 사임…외교결례 지적도(종합) | 연합뉴스
- 서울·인천·대전·충남·충북 황사경보 '관심'으로 하향 | 연합뉴스
- '수도권 위협 장사정포 감시' 대포병탐지레이더-Ⅱ 배치 완료 | 연합뉴스
- 박은정 "전관예우라면 160억 벌었어야" 조국 "혜택으로 안 보여"(종합) | 연합뉴스